Spero Therapeutics, Inc. reported a significant decline in revenue for the first quarter of 2026, generating $258,000 compared to $5.9 million in the same period of 2025. The decrease was primarily attributed to a drop in collaboration revenue from related parties, which fell from $5.1 million to $258,000. The company did not recognize any grant revenue during the quarter, a stark contrast to the $763,000 reported in the previous year. Despite the revenue decline, Spero's operating expenses also decreased significantly, totaling $7.8 million in Q1 2026, down from $20.6 million in Q1 2025, leading to a reduced net loss of $7.2 million compared to $13.9 million a year earlier.
The company's financial position showed a decrease in total assets, which fell to $59.0 million as of March 31, 2026, down from $68.9 million at the end of 2025. Cash and cash equivalents increased to $56.1 million, bolstered by a $25 million milestone payment received in February 2026 following GSK's filing of a New Drug Application (NDA) for tebipenem HBr. This milestone payment was part of the ongoing collaboration with GSK, which has been pivotal for Spero's financial strategy. The accumulated deficit as of March 31, 2026, stood at $458.3 million, reflecting the company's ongoing investment in research and development.
Strategically, Spero has focused on its collaboration with GSK, particularly regarding the tebipenem HBr program, which aims to treat complicated urinary tract infections. The pivotal Phase 3 trial for this product was stopped early for efficacy in May 2025, and the NDA was resubmitted to the FDA in December 2025, with a Prescription Drug User Fee Act (PDUFA) date set for June 18, 2026. The company has also ceased development of its earlier-stage programs, SPR206 and SPR720, to concentrate resources on tebipenem HBr and explore new opportunities for clinical-stage product candidates.
Operationally, Spero's workforce has been adjusted, with a notable reduction in personnel-related costs contributing to the decrease in overall expenses. The company reported a headcount reduction, which has led to lower general and administrative expenses, totaling $4.9 million in Q1 2026, down from $6.8 million in the prior year. The company continues to evaluate its operational needs and may seek additional funding through various means, including equity offerings and collaborations, to support its ongoing research and development efforts.
Looking ahead, Spero anticipates continued operating losses as it navigates the complexities of drug development and regulatory approval processes. The company believes its current cash reserves will be sufficient to fund operations into 2028, but acknowledges the need for additional funding to support future product development and commercialization efforts. The successful outcome of the tebipenem HBr program remains critical to Spero's financial viability and growth prospects in the competitive biopharmaceutical landscape.
About Spero Therapeutics, Inc.
Spero Therapeutics is a biopharmaceutical company focused on developing novel treatments for rare and multi-drug resistant bacterial infections. Its pipeline includes oral and IV antibiotics targeting serious infections like cUTI, HABP/VABP, and NTM pulmonary disease. The company collaborates with partners like GSK and Meiji, leveraging proprietary technology and strategic licensing to address high unmet medical needs in infectious diseases.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.